<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03494036</url>
  </required_header>
  <id_info>
    <org_study_id>804/UN2.F1/ETIK/2017</org_study_id>
    <nct_id>NCT03494036</nct_id>
  </id_info>
  <brief_title>Effect of Synbiotic on Immune Response, Gut Permeability and Microbiota in Patient With Connective Tissue Disease</brief_title>
  <official_title>Effect of Synbiotic Supplementation on Interleukin 17 (IL-17) Level, Regulatory T-cells, Gut Permeability and Microbiota in Patient With Connective Tissue Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fakultas Kedokteran Universitas Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fakultas Kedokteran Universitas Indonesia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind randomized placebo controlled trial to determine the effect of
      synbiotic to FOXP3 regulatory T cells, IL-17, gut permeability and gut microbiota in patients
      with connective tissue disease. Synbiotic can increase FOXP3 regulatory T cells, decrease
      IL-17 and improve gut permeability and gut microbiota in patients with connective tissue
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study showed gut microbiota has a role in the pathogenesis of autoimmune diseases. Gut
      microbiota which can increase gut permeability affect the antigen presentation to the immune
      system. Synbiotic supplementation is expected to improve immune system, gut permeability, and
      gut microbiota in patients with connective tissue disease.

      The subjects who fulfill inclusion criteria, willing to participate and sign informed consent
      will be randomized into two groups: the group receiving synbiotic containing probiotic
      (Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, dan Bifidobacterium
      bifidum R0071 20%) and 80 mg fructooligosaccharide (group I, n=23) and the group receiving
      placebo (group II, n=23). Both groups receive intervention for two months. Patients continue
      to receive their immunosuppressive drugs (corticosteroids, hydroxychloroquine, mycophenolate
      mofetil, azathioprine, or cyclosporine).

      Percentage of FOXP3 Regulatory T-cells, serum IL-17, zonulin, high sensitivity C-reactive
      protein, and gut microbiota are evaluated at the beginning and at the end of the study. FOXP3
      regulatory T-cell is evaluated by flowcytometry. Serum IL-17 and zonulin are measured by
      ELISA. Gut microbiota is evaluated using 16s ribosomal RNA gene next generation sequencing.
      The DNA from the stool is isolated by DNA stool mini kit (QIAamp).

      The results are presented in mean Â± standard deviation, median (IQR 25-75%) and n (%). The
      Kolmogorov-Smirnov test is used to determine the normality of the data, assuming the
      normality of the data is fulfilled if p&gt; 0.05. Bivariate analysis uses paired T test if the
      data has normal distribution. If the distribution is not normal, Wilcoxon test will be used.
      Differences are said to be significant when the value of p &lt;0.05.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FOXP3 regulatory T cell</measure>
    <time_frame>2 months</time_frame>
    <description>change in the percentage of FOXP3 regulatory T cell</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IL-17</measure>
    <time_frame>2 months</time_frame>
    <description>change in the serum IL-17 level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>zonulin</measure>
    <time_frame>2 months</time_frame>
    <description>change in the serum zonulin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut microbiota</measure>
    <time_frame>2 months</time_frame>
    <description>change of the profile of gut microbiota</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Connective Tissue Diseases</condition>
  <arm_group>
    <arm_group_label>Synbiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Synbiotic capsule containing 3x1.000.000.000 Colony Forming Units probiotics (Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, dan Bifidobacterium bifidum R0071 20%) and fructooligosaccharide 80 mg. The dosage is once daily and it is given for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule containing saccharum lactis. The dosage is once daily and it is given for 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Synbiotic</intervention_name>
    <description>capsule</description>
    <arm_group_label>Synbiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diagnosed with connective tissue disease

          -  has gastrointestinal symptoms (abdominal pain, diarrhea, constipation, or bloating)

          -  age between 18-60 years old

        Exclusion Criteria:

          -  pregnant or breastfeeding

          -  acute infection

          -  on antibiotic treatment

          -  taking yoghurt or probiotic supplementation in the last 3 weeks before recruitment

          -  taking corticosteroid more than 20 mg prednison a day or equal\

          -  refuse to join the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>alvina widhani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine University of Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>alvina widhani, MD</last_name>
    <phone>+62213904546</phone>
    <email>alvina.widhani@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cipto Mangunkusumo Hospital</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>alvina widhani, MD</last_name>
      <phone>+62213904546</phone>
      <email>alvina.widhani@gmail.com</email>
    </contact>
    <investigator>
      <last_name>alvina widhani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2018</study_first_submitted>
  <study_first_submitted_qc>March 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fakultas Kedokteran Universitas Indonesia</investigator_affiliation>
    <investigator_full_name>alvinawidhani</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>synbiotic</keyword>
  <keyword>probiotic</keyword>
  <keyword>lupus</keyword>
  <keyword>connective tissue disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

